Next Generation Payloads Designed to Transform the Therapeutic Potential of Antibody Drug Conjugates in Cancer Treatment

About Simris Group

At Simris, we are pioneering the next generation of ADC payloads to revolutionise cancer treatment. Our platform is built on the world’s largest cyanobacterial strain library and over two decades of deep scientific expertise.

Through our proprietary discovery and bioconjugation technologies, we are developing novel, IP-protected payloads with the potential to dramatically improve both the efficacy and safety of ADC therapeutics.

Simris Biologics

Discover how Simris Biologics is redefining cancer care. Our next-generation ADC payloads, designed using cyanobacterial toxin engineering, are built to outperform conventional payloads in potency, safety, and selectivity.

© 2025 Simris Group · Pioneering algae biotech since 2011. all rights reserved.

Simris Alg AB shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664. Certified Adviser is Amudova AB, telephone: +46 8 546 017 58, email: info@amudova.se.